Therapeutic potential of sulforaphane: modulation of NRF2-mediated PI3/AKT/mTOR pathway in oral fibrosis
DOI:
https://doi.org/10.4322/bds.2024.e4172Abstract
Oral Submucous Fibrosis is a potentially malignant disorder caused by habitual areca nut chewing, which contributes to the dispersion of active alkaloids into subepithelial tissues, stimulating excessive extracellular matrix deposition. Various treatment modalities are available; however, their efficacy in inhibiting fibrosis progression remains limited. Sulforaphane (SFN), an isothiocyanate found abundantly in cruciferous plants, is known to have effective antifibrotic properties. Objective: The present study investigated the antifibrotic effect of SFN via phosphatidylinositol 3 kinase (PI3K), Serine/Threonine Kinase 1 (AKT-1), mammalian target of rapamycin (mTOR) pathway in arecoline (AER) induced fibrosis in human gingival fibroblasts [HGFs]. Material and Methods: MTT assay determined the half-maximal inhibitory concentration of AER and SFN at 24h in the HGF cell line. Expression levels of transforming growth factor B1 (TGFB1), collagen type 1 alpha 2 (COL1A2), hydroxyproline (HYP), PI3, AKT, mTOR, and nuclear factor erythroid 2–related factor 2 (NRF2) were assessed post-AER and SFN treatment using qPCR and western blot analysis. Results: The findings of the study revealed that AER elicited a stimulatory effect, upregulating TGFB1, COL1A2, HYP, PI3K, AKT, and mTOR and downregulating NRF2 expression. Conversely, SFN treatment significantly upregulated NRF2, inhibiting TGFB1 mediated PI3/ AKT/mTOR pathway. Conclusion: These observations suggest that SFN can be used as a promising synergistic antifibrotic agent to combat fibrogenesis via the non-Smad pathway.
KEYWORDS
Arecoline; NRF2; Oral submucous fibrosis; PI3/AKT/mTOR; Sulforaphane.
Downloads
Published
How to Cite
Issue
Section
License
Brazilian Dental Science uses the Creative Commons (CC-BY 4.0) license, thus preserving the integrity of articles in an open access environment. The journal allows the author to retain publishing rights without restrictions.
=================
COPYRIGHT TRANSFER AND RESPONSIBILITY STATEMENT
(PDF)
For all articles published in the BDS journal, copyright is retained by the authors. Articles are licensed under an open-access Creative Commons CC BY 4.0 license, meaning that anyone may download and read the paper for free. In addition, the article may be reused and quoted, provided that the original published version is cited. These conditions allow for maximum use and exposure of the work while ensuring that the authors receive proper credit. All metadata associated with published articles is released under the Creative Commons CC0 Universal Public Domain Dedication.
Before the submission, authors must obtain permission to reproduce any published material (figures, schemes, tables, or any extract of a text) that does not fall into the public domain or for which they do not hold the copyright. Permission should be requested by the authors from the copyright holder (usually the Publisher, please refer to the imprint of the individual publications to identify the copyright holder).
The authors hereby attest that the study is original and does not present manipulated data, fraud, or plagiarism. All names listed made a significant scientific contribution to the study, are aware of the presented data, and agree with the final version of the manuscript. They assume complete responsibility for the ethical aspects of the study.
This text must be printed and signed by all authors. The scanned version should be submitted as supplemental file during the submission process.
